press release archive

Rigel to Present at New York Society of Securities Analysts Healthcare Conference

South San Francisco, CA - March 23, 2001

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present at the New York Society of Securities Analysts (NYSSA) Fifth Annual Healthcare Conference on Monday, March 26, at 9:45 a.m. EST. Brian C. Cunningham, Rigel's Chief Operating and Financial Officer, will provide an overview of Rigel's business and report on the company's portfolio of research programs in the areas of oncology, immunology and infectious diseases.

The live presentation can be accessed via Rigel's website (www.rigel.com), as well as on NYSSA's web site (www.nyssa.org), and will be available online for 30 days following the live presentation.

Rigel uses post-genomics combinatorial biology technology to discover novel drug targets. Post-genomics combinatorial biology technology is designed to identify molecules which play an important role in regulating a human cells response to disease by testing a very large number of proteins in a very large number of cells to determine which proteins will change the cells response to the disease. Rigel currently has programs in asthma/allergy, autoimmunity, transplant rejection, rheumatoid arthritis, inflammatory bowel disease, cancerous tumor growth and hepatitis C. In addition to its proprietary programs, Rigel has research and product development collaborations with Pfizer Inc., Cell Genesys, Inc., Janssen Pharmaceutica N.V. and Novartis Pharma A.G. Rigel is based in South San Francisco, California.